In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Akebia Therapeutics Inc.

www.akebia.com

Latest From Akebia Therapeutics Inc.

Roxadustat Stacks Up To Darbepoietin In Non-Dialysis Anemia

Astellas’s oral HIF-PH inhibitor shows non-inferiority to one established ESA in head-to-head trial and while there were cardiovascular benefits, the picture is complex.

Clinical Trials Blood & Coagulation Disorders

Finance Watch: Moderna Capitalizes On COVID-19 Vaccine Data Value Boost

Public Company Edition: Moderna leveraged its all-time high stock price to raise $1.34bn on the same day it reported data from a Phase I trial of its COVID-19 vaccine. Several other companies also took advantage of biopharma’s rising value.

Financing Business Strategies

Taisho Deal Gives BioAge First Clinical Asset

Private US venture moves into the clinic with early-stage asset from Japanese partner with potential in aging disorders.

Commercial Deals

Court Says FibroGen’s UK Roxadustat Patents Are Invalid

A complex and weighty judgment from the High Court regarding a new class of anemia compounds tackles a range of thorny patent law issues including obviousness, insufficiency and indirect infringement.

United Kingdom Intellectual Property
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Blood & Coagulation Disorders & Products
  • Gastrointestinal
  • Renal System
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Akebia Therapeutics Inc.
  • Senior Management
  • John P Butler, Pres. & CEO
    Jason A Amello, SVP, CFO
    Michel Dahan, SVP, CBO
    Rita Jain, MD, SVP, CMO
  • Contact Info
  • Akebia Therapeutics Inc.
    Phone: (617) 871-2098
    245 First St.
    Ste. 1100
    Cambridge, MA 02142
    USA
UsernamePublicRestriction

Register